UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045064
Receipt number R000051482
Scientific Title A Prospective Clinical Trial of Proton Radiotherapy with 12 fractions for Patients with Prostate Cancer
Date of disclosure of the study information 2021/08/16
Last modified on 2023/02/06 14:13:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Prospective Clinical Trial of Proton Radiotherapy with 12 fractions for Patients with Prostate Cancer

Acronym

Proton Radiotherapy with 12 fractions for Prostate Cancer

Scientific Title

A Prospective Clinical Trial of Proton Radiotherapy with 12 fractions for Patients with Prostate Cancer

Scientific Title:Acronym

Proton Radiotherapy with 12 fractions for Prostate Cancer

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and efficacy of the proton radiotherapy with 12 fractions for prostate cancer in Narita memorial proton center

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Early-phase (< 90 days after start of irradiation) bladder/urinary adverse event rate (>Grade 2)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

51.6GyRBE in 12 fractions with a fractional dose of 4.3GyRBE (4 times per week)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1) Histologically diagnosed primary prostate adenocarcinoma
2) Either clinical stage of T1-T3b and N0M0, in accordance with UICC (2017)
3) ECOG Performance status is 0, 1 or 2
4) Twenty years old of age at registration or more
5) Patient without active double cancer or severe basic disease
6) Patient who can keep his posture during irradiation
7) Technically being able to be irradiated
8) Written informed consent

Key exclusion criteria

1) Patient without tissue specimen of biopsy
2) Patient with past history of radiotherapy for the targeted lesion
3) Patient with past history of surgery for the target lesion
4) Patient with active and intractable infection in the targeted lesion
5) Patient who is administrated more than two anticoagulant drugs
6) Inflammatory bowel diseases or after the surgery of rectal cancer
7) Patient who cannot be put the metal marker or spacer
8) Patient with severe disease
9) Judged as inappropriate to participation by investigators

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Yuta
Middle name
Last name Shibamoto

Organization

Narita memorial proton center

Division name

Department of proton

Zip code

441-8021

Address

Shirakawa cho 78, Toyohashi, Aichi

TEL

0532-33-0033

Email

yshiba@med.nagoya-cu.ac.jp


Public contact

Name of contact person

1st name Takeshi
Middle name
Last name Yanagi

Organization

Narita memorial proton center

Division name

Department of proton

Zip code

441-8021

Address

Shirakawa cho 78, Toyohashi, Aichi

TEL

0532-33-0033

Homepage URL


Email

tyana116@meiyokai.or.jp


Sponsor or person

Institute

Narita Memorial Proton Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Narita memorial hospital ethics committee

Address

Haneihonmachi 134, Toyohashi, Aichi

Tel

0532-31-2167

Email

suzukik@meiyokai.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 08 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2021 Year 07 Month 08 Day

Date of IRB

2021 Year 07 Month 08 Day

Anticipated trial start date

2021 Year 09 Month 01 Day

Last follow-up date

2028 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 08 Month 04 Day

Last modified on

2023 Year 02 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051482


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name